[{"orgOrder":0,"company":"Jiangsu Synthgene Biotechnology","sponsor":"Jiangsu Synthgene Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Synthgene Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Synthgene Biotechnology \/ Jiangsu Synthgene Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Synthgene Biotechnology \/ Jiangsu Synthgene Biotechnology"}]
Find Clinical Drug Pipeline Developments & Deals by Jiangsu Synthgene Biotechnology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target